Sarepta Therapeutics, Inc. (SRPT) — Fair Value Analysis
Base-case fair value (P50): $22.39 · Current price: $16.78 · Verdict: Undervalued
The Verdict on SRPT
SAREPTA THERAPEUTICS INC (SRPT) is currently deemed Fairly Valued based on our proprietary Monte Carlo simulations. While the stock trades at $16.78, our median fair value estimate (P50) stands at $22.39. This suggests a potential +33.4% from its current trading level, indicating that despite some market fluctuations, SRPT's current valuation aligns reasonably with its intrinsic value profile generated across thousands of forward-looking scenarios. The "Fairly Valued" verdict reflects a balance between the company's operational health and its growth prospects relative to its current market price.
How SRPT stacks up against peers
SRPT's operational and financial health is categorized as average when compared to its broader sector. This average quality tier implies the company exhibits neither significant strength nor weakness relative to its peers, maintaining a steady, consistent performance. However, this average positioning doesn't preclude potential for investors. The Monte Carlo analysis projects a median fair value of $22.39, presenting a notable +33.4% from the current $16.78. This upside potential, even for an average quality company, highlights areas where SRPT could still offer attractive returns, driven by specific catalysts captured within our simulations.
What this means for investors
For investors, the Fairly Valued assessment of SRPT at $16.78, with a median fair value target of $22.39, suggests a calculated approach is warranted. The projected +33.4% indicates that while SRPT isn't deeply undervalued, there's still room for appreciation if the company performs in line with the median outcomes of our simulations. Understanding the full range of potential outcomes, including the downside and more optimistic scenarios, is crucial for comprehensive decision-making. To explore the complete bear-case (P10) and bull-case (P90) distribution and track SRPT’s fair value as new fundamentals are released, sign up for a free FairCurve account.
Frequently Asked Questions
Is SRPT overvalued or undervalued right now?
SAREPTA THERAPEUTICS INC (SRPT) is currently deemed Fairly Valued. Our median fair value estimate (P50) is $22.39 compared to its current price of $16.78.
What is the bear case and bull case for SRPT?
The full Monte Carlo distribution, including specific price targets for the bear case (P10) and bull case (P90) and the probability of upside, is available with a free FairCurve account.
How does FairCurve calculate SRPT's fair value?
FairCurve calculates SRPT's fair value using Monte Carlo simulation, running thousands of forward-looking financial scenarios to derive a probabilistic distribution of intrinsic values.
How can I track SRPT's fair value as it changes?
Add SRPT to your free FairCurve watchlist for daily fair-value updates and instant re-valuation whenever new earnings or other significant fundamental data are released.